Congressional Pressure Mounts on DOJ for Cannabis Rescheduling Timeline
House member demands transparency on federal cannabis rescheduling process as industry awaits regulatory clarity that could unlock billions in market value.
Congressional oversight of the cannabis rescheduling process intensifies as a House representative formally requests an update from the Department of Justice on the timeline for federal cannabis classification changes. The inquiry reflects growing impatience among lawmakers and industry stakeholders over the prolonged regulatory review that has kept cannabis stocks in limbo for months.
The rescheduling process, which could move cannabis from Schedule I to a lower classification under the Controlled Substances Act, represents the most consequential regulatory development for the cannabis sector since state-level legalization began. A successful rescheduling would eliminate the 280E tax burden that currently prevents cannabis companies from deducting standard business expenses, potentially adding hundreds of millions in annual savings across the industry.
Multi-state operators stand to benefit most dramatically from rescheduling, with companies like Curaleaf, Green Thumb Industries, and Trulieve currently paying effective tax rates exceeding 70% due to 280E restrictions. Industry analysts estimate that rescheduling could improve EBITDA margins by 15-25 percentage points for major operators, fundamentally altering cannabis company valuations and competitive dynamics.
The congressional pressure comes as cannabis stocks trade near multi-year lows despite strong operational performance from leading operators. The AdvisorShares Pure US Cannabis ETF has declined over 60% from its 2021 peaks, with regulatory uncertainty cited as a primary factor suppressing institutional investment. Banking restrictions and interstate commerce limitations continue constraining capital access and operational efficiency across the sector.
Market participants view the congressional inquiry as a potential catalyst for accelerating the rescheduling timeline, though the DOJ maintains discretion over the process pace. The outcome will determine whether cannabis companies can access traditional banking services, list on major exchanges, and operate with tax parity compared to other industries, making this regulatory decision the most critical factor for sector performance in 2026.